COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804

Article view: 267

Article download: 97

IP Indian Journal of Neurosciences


Reversal of the anticoagulant effect of direct thrombin inhibitor dabigatran etexilate in acute ischemic stroke and intracranial hemorrhage using idarucizumab – A case study


Full Text PDF Share on Facebook Share on Twitter


Case Report

Author Details : Ashutosh N Shetty*, Nasli R Ichaporia, Amod Tilak, Sonesh Kalra

Volume : 5, Issue : 3, Year : 2019

Article Page : 176-180


Suggest article by email

Abstract

The non-Vitamin K oral anticoagulants (NOACs) help prevent stroke in patients of atrial fibrillation.
However, management of patients on NOACs in emergency situations is a challenging prospect.
Idarucizumab is approved globally as well as in India as the specific reversal agent for dabigatran. We
report two cases with successful reversal using Idarucizumab in acute ischemic stroke and intracranial
hemorrhage.

Keywords: Atrial fibrillation, Bleeding, India, Stroke.

Doi : 10.18231/j.ijn.2019.028

How to cite : Shetty A N, Ichaporia N R, Tilak A, Kalra S , Reversal of the anticoagulant effect of direct thrombin inhibitor dabigatran etexilate in acute ischemic stroke and intracranial hemorrhage using idarucizumab – A case study. IP Indian J Neurosci 2019;5(3):176-180

Copyright © 2019 by author(s) and IP Indian J Neurosci. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (creativecommons.org)